Theravance is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule medicines. The company's research and development efforts are focused on four therapeutic areas: respiratory disease, gastrointestinal motility dysfunction, immunology, and infectious disease. Theravance's lead product is Vibativ, an antibiotic used to treat serious bacterial infections. The company is also developing a number of other product candidates, including TD-1473, a potential treatment for inflammatory bowel disease, and TD-8236, a potential treatment for respiratory syncytial virus. Theravance is committed to improving the lives of patients through the development of innovative medicines.